Milademetan

Milademetan
Clinical data
Other names	DS-3032
Identifiers
CAS Number	1398568-47-2;
PubChem CID	73297272;
IUPHAR/BPS	12941;
DrugBank	DB15257;
UNII	R3I80TLN7S;
KEGG	D12621;
ChEMBL	ChEMBL4292264;
Chemical and physical data
Formula	C30H34Cl2FN5O4
Molar mass	618.53 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CCC2(CC1)[C@@]3([C@H]([C@@H](N2)C(=O)N[C@@H]4CC[C@H](OC4)C(=O)N)C5=C(C(=NC=C5)Cl)F)C6=C(C=C(C=C6)Cl)NC3=O)C;
	InChI InChI=1S/C30H34Cl2FN5O4/c1-28(2)8-10-29(11-9-28)30(18-5-3-15(31)13-19(18)37-27(30)41)21(17-7-12-35-24(32)22(17)33)23(38-29)26(40)36-16-4-6-20(25(34)39)42-14-16/h3,5,7,12-13,16,20-21,23,38H,4,6,8-11,14H2,1-2H3,(H2,34,39)(H,36,40)(H,37,41)/t16-,20+,21+,23-,30-/m1/s1; Key:RYAYYVTWKAOAJF-QISPRATLSA-N;

Milademetan is an investigational new drug that is being evaluated to treat liposarcoma.^[1] It is a MDM2 inhibitor.^[2]

References

↑ "Milademetan - Rain Oncology". AdisInsight. Springer Nature Switzerland AG.
↑ Ananthapadmanabhan V, Frost TC, Soroko KM, Knott A, Magliozzi BJ, Gokhale PC, et al. (July 2022). "Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma". JCI Insight. 7 (13) e160513. doi:10.1172/jci.insight.160513. PMC 9310528. PMID 35801592.